Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 04:18:28 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Shohei Ohtani's first walk
Next:A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
You may also like
- Culture festival showcases integration
- China's Land
- Discovering Ocean's Poetic Charms
- Innovation drive in health sector boosts multinationals' confidence in Chinese market
- Who is Abi Carter? Inside the American Idol winner's unconventional family life
- 'Small Zoo' in Qingdao Welfare House Brightens Children's Life
- Providing Heartwarming Services to Children
- Inside the boom: Why German companies flock to a Chinese town
- Digital technologies restore looks of 2,200